Alto Neuroscience, Inc. (ANRO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Alto Neuroscience, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 13 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 27.10 $ — 94% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 31.5% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.15 | -3.72 – -2.58 | 0 | – | 6 |
| 12/31/2027 | -3.43 | -4.39 – -2.23 | 0 | -9.2% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.71 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.43 | – | 0 | 5.90 | -3,858.10 | -13 | -14 |
| 2025: Q1 | -0.43 | – | 0 | – | – | -17 | -17 |
| 2025: Q2 | -0.50 | – | 0 | – | – | -14 | -14 |
| 2025: Q3 | -0.40 | – | 0 | – | – | -10 | -10 |
| 2025: Q4 | -0.46 | – | 0 | -100.00 | – | -12 | -12 |
| 2026: Q1 | -0.75 | – | 0 | – | – | -27 | -28 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2021 | 0 | -12 | -9 | -0.36 | -9 | -12 | 29 |
| 2022 | 0 | -29 | -28 | -1.08 | -20 | -38 | 51 |
| 2023 | 0 | -38 | -36 | -1.35 | -33 | -72 | 87 |
| 2024 | 0 | -69 | -61 | -2.50 | -47 | 151 | 178 |
| 2025 | 0 | -66 | -63 | -2.19 | -52 | 151 | 185 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Alto Neuroscience, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase in den USA.
| Employees | 68 |
|---|---|
| Headquarters | Mountain View, CA |
| Address | 650 Castro Street, 94041 Mountain View, United States |
| Phone | 650 200 0412 |
| Website | altoneuroscience.com |
| IPO Date | 2. Feb 2024 |
| ISIN | US02157Q1094 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Amit Etkin M.D., Ph.D. | Founder, Chairman of the Board, CEO & President | 1977 |
| Nicholas C. Smith | CFO & Chief Business Officer | 1989 |
| Michael C. Hanley M.B.A. | Chief Operating Officer | 1974 |
| Dan Segal B.Sc. (Hons), BCom, CA, MSc | Co-Founder & Strategic Advisor | 1962 |
| Erin R. McQuade J.D. | General Counsel, Chief Administrative Officer & Corporate Secretary | 1975 |
| Adam Savitz M.D., Ph.D. | Chief Medical Officer | 1966 |
| Jessica Powell | Chief Development Officer | 1975 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.